Top

Archives of Gynecology and Obstetrics

Published in:

01-03-2014 | Gynecologic Oncology

Increased osteopontin expression is associated with progression from vulvar precancerous lesions to vulvar squamous cell carcinoma

Authors: Zhihong Wu, Yue Shen, Kebo Gong, Zhihua Wu, Tingguo Zhang, Xiaodan Zhang, Shuling Li

Published in: Archives of Gynecology and Obstetrics | Issue 3/2014

Abstract

Purpose

Vulvar squamous cell carcinoma (VSCC) contributes to about 3–5 % of all gynecological cancers. Vulvar intraepithelial neoplasia (VIN) and vulvar lichen sclerosus (VLS) are regarded as precancerous lesions. Early detection and treatment of precancerous lesions may prevent development of VSCC. Osteopontin (OPN) has been shown to be involved in many physiological and pathological processes, such as tumor progression, by promoting cancer cell invasion and metastasis. As a result of these findings, OPN has been described as a potential marker for tumor progression in some malignancies. In this study, we investigated the expression of OPN in vulvar tissue specimens and compared its expression between different histopathological grades.

Methods

In the present study, the expression patterns of OPN in 80 paraffin-embedded tissue specimens, including 25 VSCC samples, 21 VIN lesions and 21 VLS, in addition to 13 normal vulvar samples, were examined by the immunohistochemical method and chromogenic in situ hybridization.

Results

The intensity of OPN expression steadily increased according to the pathological grades. In addition, OPN staining was found in the extracellular matrix in VSCC.

Conclusions

Expression levels of OPN increased from VLS and VIN to VSCC, and steadily increased with the pathological stage of VSCC. Our results suggest that OPN may be associated with the progression of VSCC.

van de Nieuwenhof HP, van der Avoort IA, de Hullu JA (2008) Review of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol 68(2):131–156. doi:10.1016/j.critrevonc.2008.02.012 S1040-8428(08)00052-8 [pii]PubMedCrossRef

de Hullu JA, van der Zee AG (2006) Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol 60(1):38–58. doi:10.1016/j.critrevonc.2006.02.008 PubMedCrossRef

Hoevenaars BM, van der Avoort IA, de Wilde PC, Massuger LF, Melchers WJ, de Hullu JA, Bulten J (2008) A panel of p16(INK4A), MIB1 and p53 proteins can distinguish between the 2 pathways leading to vulvar squamous cell carcinoma. Int J Cancer 123(12):2767–2773. doi:10.1002/ijc.23857 PubMedCrossRef

van der Avoort IA, Shirango H, Hoevenaars BM, Grefte JM, de Hullu JA, de Wilde PC, Bulten J, Melchers WJ, Massuger LF (2006) Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int J Gynecol Pathol 25(1):22–29 00004347-200601000-00002[pii]PubMedCrossRef

van der Avoort IA, van der Laak JA, Otte-Holler I, van de Nieuwenhof HP, Massuger LF, de Hullu JA, van Kempen LC (2010) The prognostic value of blood and lymph vessel parameters in lichen sclerosus for vulvar squamous cell carcinoma development: an immunohistochemical and electron microscopy study. Am J Obstet Gynecol. doi:10.1016/j.ajog.2010.02.002 S0002-9378(10)00163-8 [pii]PubMed

Sanders RJ, Mainiero F, Giancotti FG (1998) The role of integrins in tumorigenesis and metastasis. Cancer Invest 16(5):329–344. doi:10.3109/07357909809084653 PubMedCrossRef

Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, Ke Y (2006) Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 118(9):2255–2261. doi:10.1002/ijc.21619 PubMedCrossRef

Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107(9):1055–1061. doi:10.1172/jci12980 PubMedCentralPubMedCrossRef

El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS (2006) The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17(6):463–474. doi:10.1016/j.cytogfr.2006.09.010 S1359-6101(06)00059-1 [pii]PubMedCrossRef

10.

Sodek J, Da Silva Batista AP, Zohar R (2006) Osteopontin and mucosal protection. J Dent Res 85(5):404–415PubMedCrossRef

11.

Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19(5–6):333–345. doi:10.1016/j.cytogfr.2008.08.001 PubMedCrossRef

12.

Yang L, Wei L, Zhao W, Wang X, Zheng G, Zheng M, Song X, Zuo W (2012) Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells. Mol Med Report 5(2):373–376. doi:10.3892/mmr.2011.679

13.

Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E (2012) Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res 31:26. doi:10.1186/1756-9966-31-26 PubMedCrossRef

14.

Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, Faria PA, Bellahcene A, Castronovo V, Gimba ER (2012) Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 72(15):1688–1699. doi:10.1002/pros.22523 PubMedCrossRef

15.

Wai PY, Kuo PC (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27(1):103–118. doi:10.1007/s10555-007-9104-9 PubMedCrossRef

16.

Lin CK, Tsai WC, Lin YC, Hueng DY (2012) Osteopontin predicts the behaviour of atypical meningioma. Histopathology 60(2):320–325. doi:10.1111/j.1365-2559.2011.04085.x PubMedCrossRef

17.

Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V, Li G (2005) Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124(5):1044–1052. doi:10.1111/j.0022-202X.2005.23680.x JID23680 [pii]PubMedCrossRef

18.

Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112(1):144–150. doi:10.1002/cncr.23147 PubMedCrossRef

19.

Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ (2008) Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem 56(1):57–66. doi:10.1369/jhc.7A7325.2007 jhc.7A7325.2007 [pii]PubMedCrossRef

20.

Buback F, Renkl AC, Schulz G, Weiss JM (2009) Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Exp Dermatol 18(9):750–759. doi:10.1111/j.1600-0625.2009.00926.x EXD926 [pii]PubMedCrossRef

21.

Briese J, Schulte HM, Bamberger CM, Loning T, Bamberger AM (2006) Expression pattern of osteopontin in endometrial carcinoma: correlation with expression of the adhesion molecule CEACAM1. Int J Gynecol Pathol 25(2):161–169. doi:10.1097/01.pgp.0000189243.49522.ae 00004347-200604000-00008 [pii]PubMedCrossRef

22.

Song JY, Lee JK, Lee NW, Yeom BW, Kim SH, Lee KW (2009) Osteopontin expression correlates with invasiveness in cervical cancer. Aust N Z J Obstet Gynaecol 49(4):434–438. doi:10.1111/j.1479-828X.2009.01027.x AJO1027 [pii]PubMedCrossRef

23.

Davidson B, Holth A, Moripen L, Trope CG, Ie Shih M (2011) Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. Hum Pathol 42(7):991–997. doi:10.1016/j.humpath.2010.10.013 S0046-8177(10)00405-3 [pii]PubMedCrossRef

24.

Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, Maeda K, Nishio K, Fukuchi Y (2001) Differential osteopontin expression in lung cancer. Cancer Lett 171(2):215–222 S0304383501006073 [pii]PubMedCrossRef

25.

Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, Jonker A, De Witt Hamer PC, Troost D, McCulloch CA, Everts V, Van Noorden CJ, Sodek J (2011) Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology 132(1):39–48. doi:10.1111/j.1365-2567.2010.03335.x IMM3335 [pii]PubMedCrossRef

26.

Imano M, Okuno K, Itoh T, Ishimaru E, Satou T, Shiozaki H (2010) Increased osteopontin-positive macrophage expression in colorectal cancer stroma with synchronous liver metastasis. World J Surg 34(8):1930–1936. doi:10.1007/s00268-010-0582-5 PubMedCrossRef

Title: Increased osteopontin expression is associated with progression from vulvar precancerous lesions to vulvar squamous cell carcinoma
Authors: Zhihong Wu
Yue Shen
Kebo Gong
Zhihua Wu
Tingguo Zhang
Xiaodan Zhang
Shuling Li
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 3/2014
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-013-3009-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased osteopontin expression is associated with progression from vulvar precancerous lesions to vulvar squamous cell carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Hysteroscopic metroplasty: reproductive outcome in relation to septum size

Expression and significance of biglycan in endometrial cancer

Anesthetic considerations for high order cesarean sections: a prospective cohort study

Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial

Cervical cytology with a diagnosis of atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a follow-up study with corresponding histology and significance of predicting dysplasia by human papillomavirus (HPV) DNA testing

Cervical Pap screening among Israeli women, 2005–2010